XOMA Declares Quarterly Preferred Stock Dividends
September 20 2021 - 7:30AM
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today
announced its Board of Directors has authorized the following cash
dividends to holders of XOMA’s Series A and Series B Cumulative
Preferred Stock:
Holders of the 8.625% Series A Cumulative
Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash
dividend equal to $0.53906 per share.
Holders of depositary shares, each representing
1/1000 of a share of XOMA’s 8.375% Series B Cumulative Perpetual
Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend
equal to $0.52344 per depositary share.
The preferred dividends will be paid on or about
October 15, 2021, to respective holders of record at the close of
business on October 1, 2021.
About XOMA CorporationXOMA is a
biotechnology royalty aggregator playing a unique role in helping
biotech companies achieve their goal of improving human
health. XOMA acquires the potential future economics
associated with pre-commercial therapeutic candidates that have
been licensed to pharmaceutical or biotechnology companies.
When XOMA acquires the future economics, the seller receives
non-dilutive, non-recourse funding they can use to advance their
internal drug candidate(s) or for general corporate purposes.
The Company has an extensive and growing portfolio with more than
70 assets (asset defined as the right to receive potential future
economics associated with the advancement of an underlying
therapeutic candidate). For more information about the
Company and its portfolio, please visit
www.xoma.com.
Forward-Looking Statements/Explanatory
NotesCertain statements contained in this press release
are forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including statements regarding the potential
of XOMA’s portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time,
and creating additional value for the stockholders. In some
cases, you can identify such forward-looking statements by
terminology such as “anticipate,” “intend,” “believe,” “estimate,”
“plan,” “seek,” “project,” “expect,” “may,” “will, “would,” “could”
or “should,” the negative of these terms or similar
expressions. These forward-looking statements are not a
guarantee of XOMA’s performance, and you should not place
undue reliance on such statements. These statements are based
on assumptions that may not prove accurate, and actual results
could differ materially from those anticipated due to certain risks
inherent in the biotechnology industry, including those related to
the fact that our product candidates subject to out-license
agreements are still being developed, and our licensees may require
substantial funds to continue development which may not be
available; we do not know whether there will be, or will continue
to be, a viable market for the products in which we have an
ownership or royalty interest; if the therapeutic product
candidates to which we have a royalty interest do not receive
regulatory approval, our third-party licensees will not be able to
market them, and the impact to the global economy as a result of
the COVID-19 pandemic. Other potential risks to XOMA meeting
these expectations are described in more detail in XOMA's most
recent filing on Form 10-K and in other SEC filings. Consider
such risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
beliefs and assumptions only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. XOMA disclaims any obligation to update any
forward-looking statement, except as required by applicable
law.
EXPLANATORY NOTE: Any references to “portfolio”
in this press release refer strictly to milestone and/or royalty
rights associated with a basket of drug products in
development. Any references to “assets” in this press release
refer strictly to milestone and/or royalty rights associated with
individual drug products in development.
As of the date of this press release, all assets
in XOMA’s milestone and royalty portfolio except Vicineum™ are
investigational compounds. Efficacy and safety have not been
established with any of these investigational assets, and there is
no guarantee that any will become commercially
available.
Investor contacts: |
|
Juliane Snowden |
Justin Frantz |
XOMA |
Solebury Trout XOMA |
+1-646-438-9754 |
+1-937-441-9731 |
juliane.snowden@xoma.com |
jfrantz@soleburytrout.com |
|
|
Media
contact: |
|
Kathy Vincent |
|
KV Consulting &
Management |
|
+1 310-403-8951 |
|
kathy@kathyvincent.com |
|
XOMA Royalty (NASDAQ:XOMAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
XOMA Royalty (NASDAQ:XOMAP)
Historical Stock Chart
From Jul 2023 to Jul 2024